Knowledge & Resources
Expert insights and knowledge on global Innovative Contracting, VBA,
Market Access and Human Performance Factors
Innovative Contracting & VBA
Articles & Whitepapers
Analysis showing orphan drug list prices significantly higher in the U.S. than in the E.U. prompts questions about future pricing considerations for gene therapies
An analysis of orphan drug prices in the US raises concerns over the sustainability of gene therapy costs. This article explores factors influencing US drug prices , the potential impact of new EU pharmaceutical legislation and how pressure to curb spiralling drug prices is falling on US policy makers.
A payer’s perspective: Is the contracting landscape for Cell and Gene Therapies unsustainable?
In recent years, the cell and gene therapy market has been touted as a promising frontier in the pharmaceutical industry. Numerous clinical trials and regulatory approvals have driven a wave of investment and innovation. However, some analyst commentary is starting to question whether the market's early momentum has begun to wane. Despite a pipeline of nearly 400 ongoing clinical trials in Europe alone, doubts remain about whether these products will make it to market and if the recent flurry of activity is sustainable.